Charles Riv Labs International Incorporated (NYSE:CRL) Could Improve Your Long Portfolio After Less Shorts Reported

November 21, 2017 - By Adrian Mccoy

 Charles Riv Labs International Incorporated (NYSE:CRL) Could Improve Your Long Portfolio After Less Shorts Reported

Investors sentiment increased to 1.37 in Q2 2017. Its up 0.48, from 0.89 in 2017Q1. It increased, as 23 investors sold Charles River Laboratories Intl. Inc shares while 90 reduced holdings. 45 funds opened positions while 110 raised stakes. 45.02 million shares or 0.40% more from 44.84 million shares in 2017Q1 were reported.
Affinity Inv Advisors Ltd Limited Liability Company stated it has 21,120 shares or 0.25% of all its holdings. Riverhead Cap Mngmt Lc holds 0.01% or 1,931 shares. Renaissance Tech reported 1.22M shares. Symphony Asset Mngmt Ltd invested in 0.08% or 6,994 shares. Icon Advisers Incorporated owns 3,000 shares for 0.02% of their portfolio. Gsa Capital Prtnrs Llp accumulated 12,640 shares. Moreover, Creative Planning has 0% invested in Charles River Laboratories Intl. Inc (NYSE:CRL) for 141 shares. Shell Asset Mngmt reported 28,469 shares. Laurion Mgmt Limited Partnership invested 0.01% of its portfolio in Charles River Laboratories Intl. Inc (NYSE:CRL). 13,860 are held by Citigroup. Voya Inv Limited Liability Co reported 0.1% of its portfolio in Charles River Laboratories Intl. Inc (NYSE:CRL). Millennium Mgmt Ltd Liability Corp owns 1.23M shares for 0.22% of their portfolio. Northern holds 436,860 shares. Bbva Compass Comml Bank Incorporated stated it has 6,004 shares or 0.04% of all its holdings. Raymond James & has invested 0% in Charles River Laboratories Intl. Inc (NYSE:CRL).

Since May 26, 2017, it had 0 insider purchases, and 2 selling transactions for $1.11 million activity. Molho Davide sold $1.02M worth of stock.

The stock of Charles Riv Labs International Incorporated (NYSE:CRL) registered a decrease of 9.89% in short interest. CRL’s total short interest was 1.11 million shares in November as published by FINRA. Its down 9.89% from 1.24M shares, reported previously. With 347,200 shares average volume, it will take short sellers 3 days to cover their CRL’s short positions. The short interest to Charles Riv Labs International Incorporated’s float is 2.39%.

About 52,456 shares traded. Charles River Laboratories Intl. Inc (NYSE:CRL) has risen 7.06% since November 21, 2016 and is uptrending. It has underperformed by 9.64% the S&P500.

Charles River Laboratories International, Inc. is an early-stage contract research company. The company has market cap of $4.79 billion. The Firm is engaged in laboratory animal medicine and science and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. It has a 24.72 P/E ratio. The Firm operates in three divisions: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Charles River Laboratories Intl. Inc (NYSE:CRL) Ratings Coverage

Among 15 analysts covering Charles River Laboratories (NYSE:CRL), 7 have Buy rating, 1 Sell and 7 Hold. Therefore 47% are positive. Charles River Laboratories had 38 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets with “Hold” on Thursday, November 2. Jefferies maintained it with “Buy” rating and $100 target in Thursday, August 4 report. The rating was initiated by Credit Suisse on Tuesday, June 21 with “Neutral”. The stock has “Outperform” rating by Wells Fargo on Thursday, January 7. On Wednesday, January 4 the stock rating was upgraded by Evercore to “Buy”. SunTrust maintained the shares of CRL in report on Thursday, November 16 with “Buy” rating. The stock has “Buy” rating by Jefferies on Tuesday, June 13. The firm earned “Hold” rating on Monday, November 13 by KeyBanc Capital Markets. Jefferies maintained Charles River Laboratories Intl. Inc (NYSE:CRL) on Monday, April 24 with “Buy” rating. The stock has “Buy” rating by Jefferies on Monday, September 11.

More notable recent Charles River Laboratories Intl. Inc (NYSE:CRL) news were published by: Seekingalpha.com which released: “Charles River Laboratories International (CRL) Q3 2017 Results – Earnings Call …” on November 09, 2017, also Seekingalpha.com with their article: “Charles River Laboratories International (CRL) Q2 2017 Results – Earnings Call …” published on August 09, 2017, Bizjournals.com published: “Charles River Laboratories to close Frederick research facility, lay off 57 …” on November 14, 2017. More interesting news about Charles River Laboratories Intl. Inc (NYSE:CRL) were released by: Globenewswire.com and their article: “Global high throughput screening market analysis and forecast to 2022 made …” published on November 21, 2017 as well as Investorplace.com‘s news article titled: “Charles River Laboratories Intl. Inc Can Keep the Run Going” with publication date: October 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.